Loading [MathJax]/jax/element/mml/optable/GeneralPunctuation.js
Review

Anti-HIV lectins and current delivery strategies

  • Received: 11 August 2017 Accepted: 14 March 2018 Published: 27 March 2018
  • Lectins, a class of carbohydrate binding agents (CBAs), have been widely studied for their potential antiviral activity. In general, lectins exert their anti-HIV microbicidal activity by binding to viral envelope glycoproteins which hinders a proper interaction between the virus and its host, thereby preventing viral entry and replication processes. Several natural lectins extracted from plant, fungi, algae, bacteria and animals, as well as boronic acid-based synthetic lectins, have been investigated against the Human Immunodeficiency Virus (HIV). This manuscript discusses the nature of HIV envelope glycoprotein glycans and their implication in lectin antiviral activity for HIV/AIDS prevention. In addition, anti-HIV lectins and their carbohydrate specificity is reported. Furthermore, current formulations of anti-HIV lectins are presented to illustrate how to overcome delivery challenges. Although antiviral lectins will continue to occupy a major stage in future microbicide research, further investigation in this field should focus on novel delivery strategies and the clinical translation of CBAs.

    Citation: Fohona S. Coulibaly, Danielle N. Thomas, Bi-Botti C. Youan. Anti-HIV lectins and current delivery strategies[J]. AIMS Molecular Science, 2018, 5(1): 96-116. doi: 10.3934/molsci.2018.1.96

    Related Papers:

    [1] Chen Liang, Hai-Feng Huo, Hong Xiang . Modelling mosquito population suppression based on competition system with strong and weak Allee effect. Mathematical Biosciences and Engineering, 2024, 21(4): 5227-5249. doi: 10.3934/mbe.2024231
    [2] Luis Almeida, Michel Duprez, Yannick Privat, Nicolas Vauchelet . Mosquito population control strategies for fighting against arboviruses. Mathematical Biosciences and Engineering, 2019, 16(6): 6274-6297. doi: 10.3934/mbe.2019313
    [3] Kala Agbo Bidi . Feedback stabilization and observer design for sterile insect technique models. Mathematical Biosciences and Engineering, 2024, 21(6): 6263-6288. doi: 10.3934/mbe.2024274
    [4] Rajivganthi Chinnathambi, Fathalla A. Rihan . Analysis and control of Aedes Aegypti mosquitoes using sterile-insect techniques with Wolbachia. Mathematical Biosciences and Engineering, 2022, 19(11): 11154-11171. doi: 10.3934/mbe.2022520
    [5] Yang Li, Jia Li . Stage-structured discrete-time models for interacting wild and sterile mosquitoes with beverton-holt survivability. Mathematical Biosciences and Engineering, 2019, 16(2): 572-602. doi: 10.3934/mbe.2019028
    [6] Liming Cai, Shangbing Ai, Guihong Fan . Dynamics of delayed mosquitoes populations models with two different strategies of releasing sterile mosquitoes. Mathematical Biosciences and Engineering, 2018, 15(5): 1181-1202. doi: 10.3934/mbe.2018054
    [7] Luis F. Gordillo . Optimal sterile insect release for area-wide integrated pest management in a density regulated pest population. Mathematical Biosciences and Engineering, 2014, 11(3): 511-521. doi: 10.3934/mbe.2014.11.511
    [8] Gerardo Chowell, R. Fuentes, A. Olea, X. Aguilera, H. Nesse, J. M. Hyman . The basic reproduction number $R_0$ and effectiveness of reactive interventions during dengue epidemics: The 2002 dengue outbreak in Easter Island, Chile. Mathematical Biosciences and Engineering, 2013, 10(5&6): 1455-1474. doi: 10.3934/mbe.2013.10.1455
    [9] Mugen Huang, Zifeng Wang, Zixin Nie . A stage structured model for mosquito suppression with immigration. Mathematical Biosciences and Engineering, 2024, 21(11): 7454-7479. doi: 10.3934/mbe.2024328
    [10] Mingzhan Huang, Shouzong Liu, Xinyu Song . Study of the sterile insect release technique for a two-sex mosquito population model. Mathematical Biosciences and Engineering, 2021, 18(2): 1314-1339. doi: 10.3934/mbe.2021069
  • Lectins, a class of carbohydrate binding agents (CBAs), have been widely studied for their potential antiviral activity. In general, lectins exert their anti-HIV microbicidal activity by binding to viral envelope glycoproteins which hinders a proper interaction between the virus and its host, thereby preventing viral entry and replication processes. Several natural lectins extracted from plant, fungi, algae, bacteria and animals, as well as boronic acid-based synthetic lectins, have been investigated against the Human Immunodeficiency Virus (HIV). This manuscript discusses the nature of HIV envelope glycoprotein glycans and their implication in lectin antiviral activity for HIV/AIDS prevention. In addition, anti-HIV lectins and their carbohydrate specificity is reported. Furthermore, current formulations of anti-HIV lectins are presented to illustrate how to overcome delivery challenges. Although antiviral lectins will continue to occupy a major stage in future microbicide research, further investigation in this field should focus on novel delivery strategies and the clinical translation of CBAs.


    As pointed out in Claessens et al. (2014), global financial crises underline the importance of innovative modelling approaches to financial markets. The quantum mechanics approach suggests an alternative way to describe the unpredictable stock market behaviour (see e.g., Baaquie (2009)).

    This paper is motivated by the quantum mechanics approach to the actuarial modelling and risk analysis as initiated in Tamturk and Utev (2018) and developed in Lefèvre et al. (2018), Tamturk and Utev (2019). We modify and adapt their methods to derive and analyze a quantum-type financial modelling. Specifically, the Schrödinger, Heisenberg, Feynman, Dirac approaches in quantum mechanics (see, e.g., Griffiths and Schroeter (2018); Parthasarathy (2012); Plenio (2002)) will be applied to the well-known option pricing models of Black and Scholes (1973) and Cox et al. (1979).

    Moreover, motivated by the data analysis of the quantum reserve process proposed in Lefèvre et al. (2018), we model the financial data as eigenvalues of certain $ 1 $ or $ 2 $-step observable operators. These data then are analyzed to identify price jumps using supervised machine learning tools such as $ k $-fold cross-validation techniques (see, e.g., Bishop (2006); Hastie et al. (2009); Wittek (2014)).

    Option pricing models using quantum techniques discussed, for example, in Baaquie(2004, 2014); Bouchaud and Potters (2003); Haven (2002) are often based on the Schrödinger wave function with Hamiltonian operator $ H $ and are mainly oriented to continuous-time markets. For discrete-time markets as considered here, following Chen(2001, 2004), , we choose the discrete-time formalism and analyze the quantum version of the Cox-Ross-Rubinstein binomial model. Then, we establish the limit of the spectral measures providing the convergence to the geometric Brownian motion model. We also identify the limit of the $ N $-step non-self adjoint bond market as a planar Brownian motion.

    The paper is organized as follows. Section 2 deals with heterogeneous quantum binomial markets. In Section 3, two convergence properties to continuous-time quantum markets are obtained. In Section 4, discrete and continuous-time quantum mechanics techniques are applied to the problem of option pricing. Section 5 is devoted to an analysis of stock market data.

    The motivation to our models come from the quantum mechanics approach to insurance proposed in Tamturk and Utev (2018, 2019), the insurance claim data analysis via quantum tools introduced in Lefèvre et al. (2018) and the non-traditional financial modelling initiated in Ma and Utev (2012) and developed in Karadeniz and Utev(2015, 2018). The quantum modelling approach is partly inspired by Baaquie (2004); Chen(2001, 2004), and Parthasarathy (2012).

    We begin by outlining some standard arguments for a quantum-type modelling (see e.g., Lefèvre et al. (2018); Parthasarathy (2012)). An observable is a linear operator (matrix) on a certain Hilbert space. The quantum product of two independent observables $ A, B $ is implemented by the tensor product of the observables $ A\otimes B $. So, $ \ln(A\otimes B) $ acts as a quantum sum of two independent observables; in particular, $ A\otimes A $ is the quantum product of two independent identical observables.

    The 1-step quantum geometric random walk is defined as a $ 2\times 2 $ matrix $ A $ with eigenvalues $ e^u, e^d $. Thus, $ A^{\otimes N} $ ($ N\geq 0 $) models the $ N $-step geometric random walk.

    The quantum type modification of the classical Cox-Ross-Rubinstein model is originated in Chen(2001, 2004). The dynamics per period is defined by two moves: $ e^u $ (the share price goes up) and $ e^d $ (the share price goes down) with $ d < 0 < u $.

    The quantum binomial model over $ N $ periods is then represented by the share price operator

    $ HSN=S0HN, $ (1)

    where the main $ 1 $-step observable $ H = A $ is a $ 2\times 2 $ self-adjoint (hermitian) matrix with eigenvalues $ e^u, e^d $ and representation

    $ A=UDU=U(eu00ed)U, $ (2)

    where $ U $ is a $ 2\times 2 $ unitary matrix.

    In the sequel, the quantum binomial model discussed will be heterogeneous with share price operator

    $ HSN=S0H1HN. $ (3)

    The motivation to this relatively new financial model comes from Lefèvre et al. (2018) quantum mechanics approach to non-life insurance and the Lamplighter group approximation to the financial modelling suggested in Ma and Utev (2012). Based on the approach to the financial data analysis developed in Ma and Utev (2012); Karadeniz and Utev(2015, 2018) (see also references therein), we treat the data as having big jumps, say $ e^u $, small jumps, say $ e^d $ or no jump. Moreover, the financial stock is observed at fixed times $ \Delta k $ but the number of jumps occurred during the time period $ ((k-1)\Delta, k\Delta] $ is not observed. For simplicity and following Lefèvre et al. (2018), we then assume there are at most two jumps per period.

    In this circumstance, the main observable operator is given, similarly to the insurance case Lefèvre et al. (2018), by

    $ H3=S0(P0I4+P1(AI2)+P2(A2)), $ (4)

    where $ I_n $ is a $ n\times n $ identity matrix, $ A $ is the $ 2\times 2 $ matrix representing the $ 1 $-step geometric move operator (2) with eigenvalues $ e^u, e^d $, and $ P_0, P_1, P_2 $ are $ 3\times 3 $ matrix projection operators corresponding to the $ 0, 1, 2 $ claim occurrence operators and defined by

    $ Pi=WDi+1|3W,i=0,1,2, $ (5)

    where $ D_{i+1|3} $ is a $ 3 \times 3 $ diagonal matrix which has all its elements equal to $ 0 $ except the $ (i+1, i+1) $-th with value $ 1 $, and $ W $ is a $ 3\times 3 $ unitary matrix.

    The share price operator over $ N $ periods is then defined as

    $ HSN=S0HN3=S0(P0I4+P1(AI2)+P2(A2))N. $ (6)

    Furthermore, when constructing the density operator, we consider the following two cases.

    Maxwell-Boltzmann statistics. In this case, the jump sizes are i.i.d. with a two-point distribution. More precisely, there are $ 0, 1, 2 $ jumps with probabilities $ \delta_0, \delta_1, \delta_2 $ given via a Poisson process, and each jump size has two possible values $ e^d, e^u $ with probabilities $ q, p $ (see also later in Section 4.1).

    Bose-Einstein statistics. In this case, the claim sizes are dependent but remain independent of the claim occurrences.

    This model makes a bridge between the traditional binomial model and the actuarial type model. In this case, the dynamics per period is defined by three moves: no change, down and up. The trinomial type financial modelling is a well established topic in finance (see e.g., Boyle (1986); Tian (1993); Leisen and Reimer (1996)).

    Now, the $ 1 $-step observable operator $ H_2 = B $ is the $ 3\times 3 $ self-adjoint matrix with eigenvalues $ e^u, 1, e^d $ corresponding to these three moves and is given by

    $ H2=B=UDU=U(eu0001000ed)U, $ (7)

    where $ U $ is now a $ 3\times 3 $ unitary matrix.

    Then, the share price operator over $ N $ periods is defined by

    $ HSN=S0HN2=S0(U)NDNUN. $ (8)

    Remarks. Notice that the heterogeneous versions of the trinomial model and the actuarial type model are available with the representation similar to (3). However, they are not treated in this paper because the main purpose for considering these two models is the non-standard data analysis (to be presented in Section 5). Although the data analysis of time dependent models is a fascinating topic, it is out of the scope of this paper.

    As mentioned in above, the quantum binomial model (1) is originated in Chen(2001, 2004). Our presentation is somewhat different and based on the algebraic tensor product properties. In addition, since heterogeneity is an important topic in option pricing (see e.g., Benninga and Mayshar (2000)), we treat a slightly more general time dependent or heterogeneous quantum binomial model (3).

    A quantum state $ \rho $ is defined as a positive self-adjoint operator with trace $ tr(\rho) = 1 $. We recall the following properties.

    Lemma 2.1. Let $ A, B, C, D $ be self-adjoint operators, $ U $ a unitary matrix, $ f $ a function of observables and $ \rho $ a quantum state. Then,

    $ tr(ABC)=tr(CAB),tr(AB)=tr(A)tr(B),(AB)(CD)=(AC)(BD),(AB)=AB,A,B0AB0,A=UDUf(A)=Uf(D)U,UρU=quantum state. $ (9)

    For simplicity, we choose a quantum state $ \rho $ as a tensor product, i.e.

    $ ρ=ρ1ρN, $ (10)

    where each $ \rho_i $ is a self-adjoint non-negative $ 2 \times 2 $ matrix such that $ tr(\rho_i) = 1 $. From Lemma 2.1, we see that $ \rho $ is a proper quantum state.

    The risk-neutral world of the quantum Black-Scholes model consists of self-adjoint non-negative $ 2 \times 2 $ matrices $ \rho_i $ that satisfy

    $ tr(ρiHi)=1+ri,i=1,,N, $ (11)

    where $ r_i $ is the risk-free interest rate for the period $ i $.

    Let us define

    $ Hi=UiDiUi,and let~ρi=UiρiUi,i=1,,N. $ (12)

    Note that the $ \tilde{\rho_i} $ are also quantum states. In addition, $ \tilde{\rho}_i $ has non-negative diagonal elements $ q_u^{(i)}, q_d^{(i)} $ and it can be shown to have the representation

    $ ˜ρi=(quixˉxqdi), $ (13)

    where

    $ qui=1+ridiuidi,qdi=1qui. $ (14)

    The transformed operator $ \tilde{\rho} $ is then obtained from Lemma 2.1 (third property) as

    $ ˜ρ=U(ρ1...ρN)U=(U1UN)(ρ1...ρN)(U1UN)=(U1ρ1U1)(UNρNUN)=˜ρ1˜ρN, $ (15)

    after using (12), and $ \tilde{\rho} $ is again a quantum state. For the classical probability case, that is when all matrices are commutative, this transform is the form of the change of measure.

    Moreover, the quantum no arbitrage condition (11) is satisfied for the transformed density, i.e.

    $ tr(~ρiDi)=1+ri,i=1,,N. $ (16)

    Consider a payoff function $ f $ and a discount factor

    $ dN=1/(1+r1)(1+rN). $ (17)

    From (3), the price of the general option without arbitrage $ OP(f(H_{S_N})) $ for the $ N $-step quantum binomial model is then defined by

    $ OP(f(HSN))=dNtr(ρf(HSN))=dNtr(ρ1...ρNf(S0H1...HN)). $ (18)

    Applying properties given in Lemma 2.1, we then obtain

    $ OP(f(HSN))=tr(ρ1...ρNf(S0H1...HN))(1+r1)(1+rN)=tr(ρ1...ρNUf(S0D1...DN)U)(1+r1)(1+rN)=tr([U(ρ1...ρN)U]f(S0D1...DN))(1+r1)(1+rN)=tr(˜ρ1˜ρNf(S0D1...DN))(1+r1)(1+rN), $ (19)

    after using (15). Since $ \tilde{\rho} $ is a tensor product and $ f(S_0 D_1 \otimes... \otimes D_N) $ is a diagonal matrix, we deduce the option pricing formula (20) below.

    Theorem 2.2. For the heterogeneous quantum binomial model,

    $ OP(f(HSN))=σf(S0yσ)qσ(1+r1)(1+rN), $ (20)

    where the index $ \sigma $ denotes any feasible path $ y_\sigma $ of the form

    $ yσ=eσ1eσNwithσi{ui,di}, $ (21)

    which occurs with the probability $ q_{\sigma} = q_{\sigma_1} \ldots q_{\sigma_N} $ where $ q_{\sigma_i} \in \{{q_{u_i}, q_{d_i}\}} $.

    In particular, for the homogeneous case (the quantum Cox-Ross-Rubinstein model) where for all $ i $, $ r_i = r, u_i = u, d_i = d $ with $ q_{u_i} = q_u, q_{d_i} = q_d $, the formula (20) reduces to

    $ OP(f(HSN))=1(1+r)NNn=0f(S0euned(Nn))qndqNnu. $ (22)

    Non-self adjoint quantum binomial market. Assume that $ H_i $ are invertible $ 2\times 2 $ matrices with two different eigenvalues $ e^d $ and $ e^u $ but no more self-adjoint, in general. In this case the transformed density $ \tilde{\rho}_i $ are no more proper states, in general. However, they still have same diagonal elements $ q_{u_i} $ and $ q_{d_i} $ and so the transformed matrix $ \tilde{\rho} $ defined in (15) again has same diagonal elements as in the self-adjoint case, but is not a proper state, in general. By inspecting the proof, we see that Theorem 2.2 holds true in this case as well.

    In this section, we consider the homogeneous quantum binomial model, and we discuss two examples on the convergence to continuous-time markets, namely the Black-Scholes model and the planar Brownian motion.

    Theorem 3.1. Let $ \mu_N $ be the measure of the eigenvalues of $ H^{\otimes N} $ with respect to the quantum state $ \rho^{\otimes N} $. Suppose that $ r = \lambda/N $ and $ u = -d = \sigma N^{-1/2} $. Then, as $ N \to \infty $,

    $ f(S0x)dμN(x)f(S0x)dμ(x), $ (23)

    where $ \mu $ is a lognormal distribution (i.e. $ \mu(x) = P(e^{a+\sigma Z} \leq x) $ for suitable constants $ a, \sigma $ and $ Z $ a standard normal variable).

    Proof. We begin with the representation via the spectral measure $ \mu_N $. Observe that

    $ Ef(HSN)=tr(ρNf(S0HN))=f(S0x)μN(dx), $ (24)

    where $ \mu_N $ is the measure of the eigenvalues $ \lambda_\sigma $ of $ H^{\otimes N} $ with respect to the quantum probability $ tr(\rho^{\otimes N} H^{\otimes N}) $. Since $ \lambda_\sigma = e^{\sigma_1} \ldots e^{\sigma_N} $ with $ \sigma_i \in \{u_i, d_i\} $, we get

    $ μN(x)=σ:λσxqσ=σ:eσ1eσNxqσ1qσN, $ (25)

    where $ q_{\sigma_i} \in \{q_u, q_d\} $ respectively.

    Let us move on to the weak convergence desired. We can write that

    $ qσ1qσN=P(Y1=eσ1)P(YN=eσN)=P(Y1=eσ1,,YN=eσN), $ (26)

    where the $ Y_i $ are i.i.d. variables with $ P(Y_i = e^{u}) = q_u, P(Y_i = e^{d}) = q_d $. Thus,

    $ μN(x)=P(Y1YNx)=P(lnY1++lnYNlnx)=P(TNlnx), $ (27)

    with $ T_N \equiv\ln Y_1+\ldots +\ln Y_N $. As $ N \to \infty $, we obtain from the central limit theorem that

    $ μN(x)=P(TNlnx)P(ea+σZx)=μ(x), $ (28)

    for certain constants $ a, b $ and $ Z $ a standard normal. This gives the limit result (23). $ \diamond $

    Remarks. (ⅰ) The limiting measure $ \mu $ corresponds to that of the geometric Brownian motion $ S_t = S_0 e^{(\rho-\sigma^2/2)t+\sigma B_t} $ when $ S_0 = 1 $, $ t = 1 $ and $ \rho-\sigma^2/2 = a $.

    (ⅱ) It would be interesting to compare the technique with the semi-classical approximation, such as expanding the action around the classical path (see (48) in Contreras et al. (2010)). Another interesting question is to analyse connection with arbitrage as discussed in Haven (2002) and Contreras et al. (2010).

    (ⅲ) The Cauchy transform is an alternative approach to deal with quantum probabilities (see Mudakkar and Utev (2013)). In particular,the convergence of spectral measures is reduced to the convergence of the Cauchy transforms. We recall that the Cauchy transform for the measure $ \mu $ is defined by

    $ Sμ(z)=Rμ(dt)tz,whereμ((a,b))=limϵ01πbaSμ(x+iϵ)dx, $ (29)

    for all $ z\in C \backslash R = \{z\in C: \Im z \neq 0\} $ and open intervals $ (a,b) $ with $ \mu(\{a,b\}) = 0 $. The goal is then to show that $ S_{\mu_n}(z) \to S_{\mu}(z) $. However,the common approach of the moment expansion does not work in this case since

    $ dμ(x)zx=k=01zk+1xkdμ(x)=k=01zk+1E(ek(a+σZ))=k=01zk+1eka+k2σ2/2=. $ (30)

    In this part,by treating the relatively simple bond market,we show that non-commutative markets provide a richer class of financial models (see also Haven (2002); Contreras et al. (2010); Herscovich (2016)).

    Bond market. Assume that returns are non-risky,that is the outcomes are equal. In the quantum setup,we suppose that matrix $ H $ has a single eigenvalue,$ e^u $ say.

    Self-adjoint quantum bond market. Let $ \rho^{\otimes N} $ denote a quantum state defined as before. Assume that in addition operator $ H $ is self-adjoint. Then $ H = e^uI_2 $ and

    $ HSN=S0HN=S0euNIN2andf(HSN)=f(S0euN)IN2. $ (31)

    In particular,any option claim $ f(H_{S_N}) $ is commutative with the state $ \rho^{\otimes N} $ which implies that the self-adjoint quantum bond market is commutative,that is equivalent to the simple classical probability financial market with two non-risky assets. The no-arbitrage condition becomes global to give $ e^u = tr(\rho H) = 1+r $ since $ tr(\rho) = 1 $ which restates that under no-arbitrage the non-risky returns are equal. Moreover,the option price for $ f(H_{S_N}) $ is provided by

    $ OP(f(HSN))=tr(ρNf(S0HN))(1+r)N=euNf(S0euN). $ (32)

    Non self-adjoint quantum bond market. Now,assume that $ H $ is no longer self-adjoint,for example a product of two noncommutative self adjoint observables. Thus,non self-adjoint quantum bond market is noncommutative,in general. In this case,we show that the limit is sensitive to the density state $ \rho $ and the representation of $ H $. For simplicity,we assume that the basic observable $ H $ and the state $ \rho $ are defined by

    $ Hu=(eu100eu100eu),ρ=(ρ11yδyρ220δ0ρ33), $ (33)

    i.e.,$ H_u $ is now a $ 3\times 3 $ Jordan matrix. The bond price process is then defined by

    $ HSN=S0HNu. $ (34)

    To satisfy the no-arbitrage condition,we ask that

    $ tr(ρHu)=1+r,thusy=1+reu. $ (35)

    Theorem 3.2. Suppose that $ r = \lambda/N $,$ u = a/N $ and $ \delta = -\Delta/N $ with $ \Delta\geq 0 $. Then,for any positive integer $ k $,as $ N \to \infty $,

    $ OP([HSN]k)eλSk0E[ek(λ+Δ/2+iBΔ)], $ (36)

    regardless of $ a $, where $ i $ is the imaginary unit and $ B_{\Delta} $ is a Brownian motion at time $ \Delta $.

    Proof. Notice that

    $ Hku=(ekue(k1)uke(k2)uk(k1)/20ekue(k1)uk00eku). $ (37)

    From the definition of $ H_{S_N} $ and $ \rho $, we then get

    $ OP([HSN]k)=OP([S0(HN)]k)=(1+r)Ntr(ρN[S0(HN)]k)=(1+r)Ntr(Sk0ρN[(Hk)N])=Sk0(1+r)Ntr([ρHk]N)=Sk0(1+r)N(ρ11euk+ρ22euk+ρ33euk+yeu(k1)k+δe(k2)uk(k1)/2)N=Sk0(1+r)N(euk+yeu(k1)k+δe(k2)uk(k1)/2)N=Sk0(1+r)N[1+ak/N+(λa)k/NΔk(k1)/2N+O(1/N2)]NSk0eλe(λ+Δ/2)kk2Δ/2 $ (38)

    after using the assumptions made on $ r, u, \delta $. This provides the limit result (36). $ \diamond $

    Remarks. (ⅰ) This representation is useful in computing the European call option OP$ ([H_{S_N}-K)_+]) $ via the Fourier techniques combined with the Monte Carlo approximation. For the distribution of this process, we view $ R^2 $ as the complex plane and the planar Brownian motion $ \tilde{B_t} = (B_1(t), B_2(t)) $ is then interpreted as a complex-valued Brownian motion.

    (ⅱ) Although observables are traditionally considered to be self-adjoint, the non self-adjoint data is modelled by considering an observable such as $ H = AB $, i.e. the product of two self-adjoint matrices $ A, B $ where $ A $ and $ B $ may represent the non-trade and trade time changes, respectively.

    (ⅲ) Similarly to the convergence to the Black-Scholes model, the limit does not depend on the shift parameter $ a $. However, now the limit depends on the mysterious characteristic $ \Delta $.

    In this section, we will apply some methods of quantum mechanics to finance. Discrete and continuous-time markets must be treated separately because of different stochastic behaviors. To simplify the presentation, we assume that the interest rate is $ 0 $ and that the risky processes for share prices are martingales.

    The use of Dirac-Feynman quantum mechanics techniques for insurance risk modelling was initiated in Tamturk and Utev (2018) and then developed in Lefèvre et al. (2018); Tamturk and Utev (2019). We adapt this approach to the problem of option pricing in finance, in particular for the pricing of path-dependent options.

    In the Dirac formalism, bra-ket notation is a standard way of describing quantum states. Consider a class of $ n\times n $ matrices treated as $ C^* $ algebra. A column vector $ x $ corresponds to a ket-vector $ |x > $. An associated bra-vector $ < x| $ is a row vector defined as its Hermitian conjugate. The usual inner product is denoted by $ < x|y > $, while the outer product $ |x > < y| $ is the operator/matrix defined by

    $ |x><y||z>=<y|z>|x>(abc=bca rule). $ (39)

    In the Feynman path integral methods, the transition probability $ P(x_j\to x_{j+1}) $ is computed as the propagator $ < x_j|A_{j+1}|x_{j+1} > $ when $ A_j $ is a Markovian operator. Thus, the typical path is written as $ |x_0 > \to |x_1 > \to \ldots \to |x_{n} > $, and its probability is given by

    $ P(|x0>→|x1>→|x2|xn>)=<x0|A1|x1><x1|A2|x2><xn1|An|xn>. $ (40)

    The main ingredient is then the path calculation formula that calculates the probability $ P(x_0 \to x_n) $ via the sum of the probabilities on all the appropriate paths, i.e.

    $ P(x0xn)=<x0|A1A2An|xn>=x1,,xn1<x0|A1|x1><x1|A2|x2><xn1|An|xn>. $ (41)

    It remains to define a suitable propagator for discrete time. For simplicity, we take the operators $ A_j $ all equal to $ A $ and the time intervals $ \Delta t_i $ all equal to $ \Delta t $. In a similar way to e.g. Baaquie (2004); Tamturk and Utev (2018), we assume that the operator $ A $ is defined via an Hamiltonian operator $ H $ such as $ A = e^{-\Delta t \, H} $, where $ -H $ is a Markovian generator called Markovian Hamiltonian. Thus, $ P(x_i\rightarrow x_{i+1}) = < x_i|e^{-\Delta t\; H}|x_{i+1} > $ which can be computed applying the Fourier transform to the momentum space (e.g., Griffiths and Schroeter (2018); Tamturk and Utev (2018)). Specifically, let $ |p > $ be a basis in that space, and write $ < x|p > = e^{ipx} $ and $ < p|x > = e^{-ipx} $. Then, we get

    $ <xi|eΔtH|xi+1>=2π0dα2π<xi|eΔtH|α><α|xi+1>=2π0dα2π<xi|α><α|xi+1>eΔtKα=12π2π0(eixiαeixi+1α)eΔtKαdα, $ (42)

    where $ \{|\alpha > , K_{\alpha}\} $ is the set of eigenvectors and eigenvalues of the Hamiltonian operator $ H $ (i.e., $ H|\alpha > = K_{\alpha} |\alpha > $). Therefore, we deduce from (41), (42) that

    $ P(x0xn)=x1,,xn1<x0|eΔtH|x1><x1|eΔtH|x2><xn1|eΔtH|xn>=x1,,xn11(2π)n2π02π02π0[n1i=0(eixiαieixi+1αi)eΔtKαi]dα0dα1dαn1. $ (43)

    For a more detailed overview of the theory, we refer the reader to the books by Feynman and Hibbs (2010); Griffiths and Schroeter (2018); Parthasarathy (2012) and Plenio (2002).

    Option pricing formula. Consider a claim of the form $ C = f(S_0, S_1, ..., S_N) $, using the notation of Section 2. From (43), we obtain for the corresponding option price

    $ OP(C)=dNS0,S1,...,SNf(S0,S1,...,SN)<S0|A1|S1><SN1|AN|SN>. $ (44)

    The discrete-time approach followed to derive (43) can then be easily applied to the current formula (44).

    A modified Cox-Ross-Rubinstein model. Consider a discrete-time market in which, during each $ i $-th time interval $ \Delta t $, the share price $ S_{i} $ can

    (.) have $ 1 $ jump giving $ S_{i+1} = S_{i}e^u, S_{i}e^d $ with probabilities $ p, q = 1-p $, or

    (.) have $ 2 $ jumps giving $ S_{i+1} = S_{i}e^{u+d}, S_{i}e^{2u}, S_{i}e^{2d} $ with probabilities $ 2pq, p^2, q^2 $, or

    (.) remain the same giving $ S_{i+1} = S_i $,

    where $ d, u $ are integers with $ d < 0 < u $. Furthermore, the possible jumps arrive according to a Poisson process of parameter $ \lambda $ so that

    (.) $ \delta_1\equiv P[N(\Delta t) = 1] = e^{-\lambda \Delta t}(\lambda \Delta t) $,

    (.) $ \delta_2\equiv P[N(\Delta t) = 2] = e^{-\lambda \Delta t}(\lambda \Delta t)^2/2 $,

    (.) $ \delta_0\equiv P[N(\Delta t) = 0] \approx 1-\delta_1-\delta_2 $.

    Define $ x_i = \ln(S_i) $. The transition probabilities $ P(S_i\to S_{i+1}) $ are equivalent to $ P(x_i\to x_{i+1}) $. Set $ \Delta_t = 1 $, say. We can now apply (42) with $ A = e^{-H} $ where the set $ \{|\alpha > , K_{\alpha}\} $ is found by solving the Schrödinger equation $ e^{-H}|\alpha > = e^{-K_{\alpha}}\, |\alpha > $ in which

    $ eH|α>(x)=Ex(eiαxi+1)=eiαx(δ0+eiαupδ1+eiαdqδ1+eiα2up2δ2+eiαx2dq2δ2+eiα(u+d)2pqδ2). $ (45)

    Notice that the Hamiltonian $ H $ is not Markovian, but (42) is still applicable to the discrete times $ k\Delta t $. Moreover, by construction, the martingale probabilities $ p = q_u $ and $ q = q_d $ for the Cox-Ross-Rubinstein model (without interest) yield a martingale in the present situation too since we have

    $ E(Si+1|Si)=Si[δ0+δ1(queu+qded)+δ2(e2uq2u+e2dq2d+eq+d2quqd)]=Si(δ0+δ1+δ2)=Si. $ (46)

    We have illustrated numerically the option pricing results obtained for the model. The tables and figures are however too large to be included here.

    This short part is mostly a review of the application of quantum mechanics approach to the continuous time markets and closely follows Baaquie (2004).

    The continuous time formalism is based on the Fourier transform of tempered distributions on the basis $ |p > $ in the momentum space. Consider a risky asset price $ S_t $ that evolves in function of an Hamiltonian operator $ H $. First, the method is applied to compute the pricing kernel

    $ p(x,τ;x)=<x|eτH|x>=dp2π<x|eτH|p><p|x>. $ (47)

    Then, the option price at time $ t $ for the claim $ Q\equiv Q(S_T) $, $ T > t $, given $ S_t = x $ is defined by

    $ OP(Q(ST)|St=x)=<x|e(Tt)H|Q>. $ (48)

    Black-Scholes model. In this classical approach, the stock price $ S_t $ follows a geometric Brownian motion, i.e. $ S_t = S_0 e^{{\tilde B}_t} $ where $ {\tilde B}_t = \mu t+\sigma B_t $ ($ \mu $ is the drift, $ \sigma $ the volatility and $ B_t $ a standard Brownian motion).

    We apply the quantum mechanics approach. Motivated by Baaquie (2004), we work with $ {\tilde B}_t $ rather than with $ S_t $. The corresponding Hamiltonian for the Brownian motion is $ Hf = -(1/2)f''-\mu f' $ (computed, for example, via the Itô formula). The Brownian motion kernel is then defined from (47) by the normal density function

    $ p(u,τ;u)=fN(τμ,τσ2)(uu)=12πτσ2exp[(1/2τσ2)(uuτμ)2]. $ (49)

    To obtain the option price (48), we set $ x = S_0e^u $ and $ Q(x) = Q(S_0e^u)\equiv g(u) $. Then, the Feynman-Kac formula yields

    $ OP(Q(ST)|St=x)=<u|e(Tt)H|g>=<u|e(Tt)H|u>g(u)du=p(u,Tt;u)Q(S0eu)du. $ (50)

    Via path integrals. To find the pricing kernel $ p(x, \tau; x') = < x|e^{-\tau H}|x' > $ for $ \tau = T-t $, an alternative method consist in using path integral methods. For this, we discretize the time in $ N $ intervals of length $ \Delta $ and consider the $ x_i = x(t_i) $ where $ t_i = i \Delta $. We then proceed as in the situation in discrete-time. The pricing kernel for $ (x, x') = (x_0, x_N) $ becomes

    $ p(x,NΔ;x)=dx1dx2dxN1Ni=1<xi1|eΔH|xi>. $ (51)

    Applications to non-life insurance. Consider Feynman's modification $ \tilde{H} $ of the Brownian motion Hamiltonian $ H $ by adding the potential $ V $, i.e. for the Hamiltonian $ \tilde{H} = H+V $. For example, choose a ruin level $ B $ and take $ V(x) = +\infty $ for $ x < B $. Then, the path calculation formula (43) allows us to compute ruin probabilities when $ B = 0 $ (Tamturk and Utev (2018, 2019)) and exotic options with barriers when $ B > 0 $.

    Finally, let us mention that numerically, the binomial model formula (20) and the path integral approach (51) were found to give results close to the Black-Scholes formula, even for relatively small values of $ N $ (of order $ 40 $).

    We are going to analyse a generated set of financial data by choosing two different quantum models described in Section 2.1. First, we consider the quantum actuarial-type model (see Section 2.1.3 and in 4.1) with the $ N $-step observable defined in (6). Then, we consider the quantum trinomial model (see Section 2.1.2) with the $ N $-step observable defined in (8). Note that matching $ 1 $-step for the actuarial case to two steps for the trinomial model is natural, since in the actuarial case, we choose at most two jumps.

    We apply supervised machine learning methods such as developed e.g. in the books by Bishop (2006); Hastie et al. (2009) and Wittek (2014).

    Overall approach. The dataset is supposed to come from a non-ordered class of randomly perturbed observables. Each data is the observation of an eigenvalue $ \lambda $ of the observable perturbed by i.i.d. error terms. The observable is the $ 1 $-step operator for the actuarial-type model and the $ 2 $-step oparator for the trinomial model. Matching $ 1 $-step in the actuarial case to $ 2 $-step in the trinomial case is natural since there are at most two jumps in the actuarial case considered.

    First, the data are classified in classes $ G_\lambda $ with respect to the eigenvalues $ \lambda $. Then, the probabilities $ p_\lambda $ are estimated by maximum likelihood using Maxwell-Boltzmann or Bose-Einstein statistics. Finally, the $ \lambda $ are estimated via the weighted $ L_1 $-norm risk error function.

    Let us explain in more detail for the actuarial-type model, for example.

    Step 1. An initial $ (u = u_0, u = d_0) $ is chosen randomly.

    Step 2. For a given $ (u, d) $, the data is classified and labeled against the eigenvalues of the observable using a nearest neighbor algorithm. This leads to the classes $ G_{\lambda} $.

    Step 3. For the same $ (u, d) $, the estimates $ \hat{p} $ and $ \hat{q} $ are obtained by maximizing the likelihood function $ L(p, q). $

    Step 4. The $ (u, d) $ is updated by minimizing a weighted $ L_1 $-norm risk error function $ F(u, d) \equiv F(\lambda) $ defined by

    $ F(λ)= $ (52)

    Step 5. The loop of steps 2 to 4 is repeated until the relative error becomes smaller than a selected difference $ M $, i.e. when

    $ \begin{equation} |F(u_{i+1}, d_{i+1})-F(u_{i}, d_{i})| \lt M. \end{equation} $ (53)

    $ k- $fold cross-validation. To reduce the risk of error, we use a $ k- $fold cross-validation strategy. The dataset is randomly divided into $ k $ subsets of equal size. One of the subsets is chosen as the training set and the others as test sets. The process is repeated $ k $ times, each subset constituting a training element. At each iteration, steps 1 to 5 above are applied to the training data and the results obtained are then checked in the test data. Finally, the estimates used are an average of those obtained on the k iterations.

    Numerical example. As a simple illustration, we will consider the following dataset

    $ \begin{equation} V = \{86, 63, 35, 52, 41, 8, 24, 12, 19, 24, 42, 5, 91, 95, 50, 49, 34, 91, 37, 11\}. \end{equation} $ (54)

    From the assumptions of the model, the $ 1 $-step observable $ H $ has the eigenvalues

    $ \begin{equation} \{\lambda\} = \{1, e^{d}, e^{u}, e^{d+u}, e^{2d}, e^{2u}\}, \end{equation} $ (55)

    with probabilities respectively given by

    $ \begin{equation} \{p_\lambda\} = \{\delta_0, q\delta_1, p\delta_1, p_{d+u}\delta_2, p_{2d}\delta_2, p_{2u}\delta_2\}. \end{equation} $ (56)

    For the probabilities $ p_{d+u}, q_{2d}, p_{2u} $, we consider two possible statistics often used in the analysis of quantum observables.

    Maxwell-Boltzmann independence. This case yields the binomial model since

    $ \begin{equation} p_{d+u} = 2pq, \, p_{2d} = q^2, \, p_{2u} = p^2. \end{equation} $ (57)

    Bose-Einstein dependence. In this case, corresponds to probabilities

    $ \begin{equation} p_{d+u} = Cpq, \, p_{2d} = Cq^2, \, p_{2u} = Cp^2, \quad \mbox{where } C(pq+q^2+p^2) = 1. \end{equation} $ (58)

    As pointed out in Lefèvre et al. (2018), both statistics admit a formal construction, via the proper choice of the density operator $ \rho $ for the number of occurrences and the density projection operators $ \rho_\lambda $, such that

    $ \begin{equation} tr(\rho \otimes \rho_{\lambda}) = p_\lambda. \end{equation} $ (59)

    Likelihood functions. Denote by $ \#x $ the number of $ x $ observed in the data set. For the Maxwell-Boltzmann statistics, the likelihood is defined by the probabilities $ p $, $ q $, $ \delta_0 $, $ \delta_1 $ and $ \delta_2 $ such that

    $ \begin{equation} L(p, q) = L(p, q, \delta_0, \delta_1, \delta_2) = (\delta_0)^{\#0}(q\delta_1)^{\#d}(p\delta_1)^{\#u}(2pq\delta_2)^{\#u+d}(q^2\delta_2)^{\#2d}(p^2\delta_2)^{\# 2u}. \end{equation} $ (60)

    For the Bose-Einstein statistics, the likelihood function is modified as

    $ \begin{equation} L(p, q) = L(p, q, \delta_0, \delta_1, \delta_2) = (\delta_0)^{\#0}(q\delta_1)^{\#d}(p\delta_1)^{\#u}(Cpq\delta_2)^{\#u+d}(Cq^2\delta_2)^{\#2d}(Cp^2\delta_2)^{\# 2u}. \end{equation} $ (61)

    Risk functions. From (55), the scaled share price spectrum of $ H_{S_1} $ is given by $ S_0\{\lambda\} = \{S_0, S_0e^{u}, S_0 e^{d}, S_0e^{u+d}, S_0e^{2d}, S_0e^{2u}\} $. Thus, using the risk function (52), we get for the Maxwell-Boltzmann case

    $ \begin{align} F_1(u, d)& = \delta_0 \sum\limits_{\beta_i \in G_{0}}|\beta_i-S_0|+q\delta_1\sum\limits_{\beta_i \in G_{d}}|\beta_i-S_0e^{d}|p\delta_1\sum\limits_{\beta_i \in G_{u}}|\beta_i-S_0e^{u}| \\ &+2pq\delta_2\sum\limits_{\beta_i \in G_{u+d}}|\beta_i-S_0e^{u+d}|+q^2\delta_2\sum\limits_{\beta_i \in G_{2d}}|\beta_i-S_0e^{2d}|+p^2\delta_2\sum\limits_{\beta_i \in G_{2u}}|\beta_i-S_0e^{2u}|, \end{align} $ (62)

    and for the Bose-Einstein case,

    $ \begin{align} F_2(u, d)& = \delta_0 \sum\limits_{\beta_i \in G_{0}}|\beta_i-S_0|+q\delta_1\sum\limits_{\beta_i \in G_{d}}|\beta_i-S_0e^{d}|+p\delta_1\sum\limits_{\beta_i \in G_{u}}|\beta_i-S_0e^{u}| \\ &+Cpq\delta_2\sum\limits_{\beta_i \in G_{u+d}}|\beta_i-S_0e^{u+d}|+Cq^2\delta_2\sum\limits_{\beta_i \in G_{2d}}|\beta_i-S_0e^{2d}|+Cp^2\delta_2\sum\limits_{\beta_i \in G_{2u}}|\beta_i-S_0e^{2u}|. \end{align} $ (63)

    Numerical illustration. The data (54) is treated as the eigenvalues of the $ 1 $-step observable $ H $ defined in (6) for $ N = 1 $. Let us assume that the Poisson process rate is $ 1 $ and the length of time is $ \Delta t = 1 $.

    We estimate the values $ d, u $ and the probabilities $ q, p $ by applying the algorithm of Section 5.1 and using the Maxwell-Boltzmann statistics. Choose, for instance, $ S_0 = 70 $, $ (u_0, d_0) = (0.8, -0.1) $ and $ M = 0.000001 $. The results obtained from (60), (62) are presented in Table 1.

    Table 1.  Estimation for $ N = 1 $ in the Maxwell-Boltzmann case.
    Given (u, d)Maximum likelihoodOptimum (p, q)Optimum (u, d)Risk error $ F(u, d) $$ |F(u_i, d_i)- $$ F(u_{i+1}, d_{i+1})| $
    (0.8, -0, 1)4.6063e-14(0.01, 0.99)(0.3, -0.4)43.310743.3107
    (0.3, -0.4)2.2681e-18(0.16, 0.84)(0.3, -0.5)22.873420.4373
    (0.3, -0.5)5.1730e-19(0.23, 0.77)(0.3, -0.6)15.86547.0080
    (0.3, -0.6)1.7631e-18(0.24, 0.76)(0.3, -0.7)14.47411.3913
    (0.3, -0.7)1.2479e-19(0.29, 0.71)(0.3, -0.7)11.19763.2765
    (0.3, -0.7)1.2479e-19(0.29, 0.71)(0.3, -0.7)11.19760

     | Show Table
    DownLoad: CSV

    We then also apply a $ 4 $-foldcross-validation procedure. Let $ V_i $, $ 1\leq i \leq 4 $, before randomly chosen subsets of $ V $ such that $ \cup_{i = 1}^{4} V_i = V $. For each iteration, $ \{V\setminus V_i\} $ and $ V_i $ are treated as the training set and the test set, respectively. First, the maximum likelihood estimation and the risk error computation are executed for the training data. Then, the obtained estimates are implemented in the test data. This gives the results of Table 2.

    Table 2.  Using a $ 4 $-fold cross-validation strategy.
    Training dataTest data
    Training & Test dataOptimum $ (u, d) $Risk error $ F(u, d) $Optimum $ (u, d) $Risk error $ F(u, d) $Total risk error function
    $ \{V\setminus V_1\}, V_1 $(0.2, -0.4)9.5462(0.2, -0.5)0.08429.6304
    $ \{V\setminus V_2\}, V_2 $(0.2, -0.3)11.1223(0.2, -0.1)0.192811.3151
    $ \{V\setminus V_3\}, V_3 $(0.2, -0.3)8.0269(0.3, -0.4)0.20428.2311
    $ \{V\setminus V_4\}, V_4 $(0.2, -0.6)9.2466(0.4, -0.7)0.06299.3095

     | Show Table
    DownLoad: CSV

    We observe that the risk errors are small for the test data but are larger for the training data. Thus, the total risk errors are significant. Similar numerical calculations have also been performed under the Bose-Einstein assumption.

    The spectrum of $ H^{\otimes N}_2 $ is given by

    $ \begin{equation} \{\lambda\} = \{e^{(N-i-j)u+id}, \, 0\leq j \leq N, 0\leq i \leq N-j\}. \end{equation} $ (64)

    Thus, for the case $ N = 2 $, the set of observables is exactly the same as (55). However, the associated probabilities differ from (56) and are equal to

    $ \begin{equation} \{p_\lambda\} = \{p_2^2, 2p_2p_3, 2p_1p_2, 2p_1p_3, p_3^2, p_1^2\}. \end{equation} $ (65)

    Likelihood and risk functions. Using the Maxwell-Boltzmann statistics, the likelihood is defined by the probabilities $ p_1 $, $ p_2 $, $ p_3 $ as

    $ \begin{equation} L(p_1, p_2, p_3) = (p_2^2) ^{\#0}(2p_2p_3) ^{\#d}(2p_1p_2) ^{\#u}(2p_1p_3) ^{\#d+u}(p_3^2) ^{\#2d}(p_1^2) ^{\#2u}. \end{equation} $ (66)

    Note that for the Cox-Ross-Rubinstein model, $ p_2 = 0 $ so that the likelihood is simplified to $ L(p_1, p_3) = (2p_1p_3) ^{\#d+u}(p_3^2) ^{\#2d}(p_1^2) ^{\#2u} $.

    The corresponding risk function is then defined by

    $ \begin{align} F_3(u, d)& = p_2^2\sum\limits_{\beta_i \in G_{0}}|\beta_i-S_0| + 2p_2p_3\sum\limits_{\beta_i \in G_{d}}|\beta_i-S_0e^{d}|+ 2p_1p_2\sum\limits_{\beta_i \in G_{u}}|\beta_i-S_0e^{u}| \\ &+ 2p_1p_3\sum\limits_{\beta_i \in G_{d+u}}|\beta_i-S_0e^{u+d}| + p_3^2\sum\limits_{\beta_i \in G_{2d}}|\beta_i-S_0e^{2d}| + p_1^2\sum\limits_{\beta_i \in G_{2u}}|\beta_i-S_0e^{2u}|. \end{align} $ (67)

    Numerical illustration. We process the data (54) again with $ S_0 = 70 $, $ (u_0, d_0) = (0.8, -0.1) $ and $ M = 0.000001 $. The results obtained using the algorithm of Section 5.1 with the functions (66), (67) are given in Table 3.

    Table 3.  Estimation for $ N = 2 $ in the Maxwell-Boltzmann case.
    Given (u, d)Maximum likelihoodOptimum $ (p_1, p_2, p_3) $Optimum (u, d)Risk error $ F(u, d) $$ |F(u_i, d_i)- $$ F(u_{i+1}, d_{i+1})| $
    (0.8, -0.1)7.3122e-10(0.01, 0.22, 0.77)(0.5, -0.4)0.03210.0321
    (0.5, -0.4)2.2847e-11(0.1, 0.18, 0.72)(0.8, -0.5)0.32960.2975
    (0.8, -0.5)7.4285e-12(0.1, 0.23, 0.67)(0.8, -0.5)0.33020.0006
    (0.8, -0.5)7.4285e-12(0.1, 0.23, 0.67)(0.8, -0.5)0.33020

     | Show Table
    DownLoad: CSV

    Then, we apply a $ 4 $-fold cross-validation procedure as previously done. The obtained results are shown in Table 4. Note that this method allows to reduce the risk errors.

    Table 4.  Using a $ 4 $-fold cross-validation strategy.
    Training dataTest data
    Training & Test dataOptimum $ (u, d) $Risk error $ F(u, d) $Optimum $ (u, d) $Risk error $ F(u, d) $Total risk error function
    $ \{V\setminus V_1\}, V_1 $(0.3, -0.1)0.1093(0.3, -0.2)0.08600.1953
    $ \{V\setminus V_2\}, V_2 $(0.3, -0.1)0.1843(0.7, -0.6)0.00570.1900
    $ \{V\setminus V_3\}, V_3 $(0.8, -0.5)0.1591(0.8, -0.6)0.01380.1729
    $ \{V\setminus V_4\}, V_4 $(0.7, -0.4)0.2575(0.8, -0.6)0.07210.3296

     | Show Table
    DownLoad: CSV

    The observable operators of the quantum actuarial-type and trinomial models give us different results as expected. Which model to choose? One possible approach might be to consider a mixture of quantum models via the mixture of Hamiltonians (see, e.g., Wittek (2014)).

    Several quantum type financial models are constructed that benefit from the physical interpretation of the unpredictable stock market behaviour and associated dependences. The models provide a general physical type framework for pricing of derivatives and a possibility to construct quantum trading strategies. Moreover, it is revealed that certain quantum type models are applied both in actuarial and financial sciences.

    C. Lefèvre received support from the Chair DIALog sponsored by CNP Assurances. S. Utev benefited from a Scientific Mission granted by the Belgian FNRS. We thank the referees for the careful reading of the paper which greatly helped to improve the presentation.

    All authors declare no conflicts of interest in this paper.

    [1] Hodder SL, Justman J, Haley DF, et al. (2010) Challenges of a hidden epidemic: HIV prevention among women in the United States. J Acquir Immune Defic Syndr 55 Suppl 2: S69–S73.
    [2] Shattock RJ, Rosenberg Z (2012) Microbicides: Topical prevention against HIV. Cold Spring Harb Perspect Med 2: a007385.
    [3] UNAIDS. Available from: http://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016.
    [4] Swanson MD, Winter HC, Goldstein IJ, et al. (2010) A lectin isolated from bananas is a potent inhibitor of HIV replication. J Biol Chem 285: 8646–8655. doi: 10.1074/jbc.M109.034926
    [5] Murphy EM, Greene ME, Mihailovic A, et al. (2006) Was the "ABC" approach (abstinence, being faithful, using condoms) responsible for Uganda's decline in HIV? PLoS Med 3: 1–5.
    [6] Cohen SA. Available from: https://www.guttmacher.org/gpr/2004/11/promoting-b-abc-its-value-and-limitations-fostering-reproductive-health.
    [7] Sovran S (2013) Understanding culture and HIV/AIDS in sub-Saharan Africa. Sahara J 10: 32–41.
    [8] Reniers G, Watkins S (2010) Polygyny and the spread of HIV in sub-Saharan Africa: A case of benign concurrency. Aids 24: 299–307. doi: 10.1097/QAD.0b013e328333af03
    [9] Helweglarsen M, Collins BE (1994) The UCLA Multidimensional Condom Attitudes Scale: Documenting the complex determinants of condom use in college students. Health Psychol 13: 224–237. doi: 10.1037/0278-6133.13.3.224
    [10] UNAIDS. Available from: http://www.unaids.org/globalreport/Global_report.htm.
    [11] Qian K, Morris-Natschke SL, Lee KH (2009) HIV entry inhibitors and their potential in HIV therapy. Med Res Rev 29: 369–393. doi: 10.1002/med.20138
    [12] Fohona S, Coulibaly BBC (2017) Current status of lectin-based cancer diagnosis and therapy. AIMS Mol Sci 4: 1–27.
    [13] Hansen TK, Gall MA, Tarnow L, et al. (2007) Mannose-binding lectin and mortality in type 2 diabetes. Arch Intern Med 166: 2007–2013.
    [14] Guan LZ, Tong Q, Xu J (2015) Elevated serum levels of mannose-binding lectin and diabetic nephropathy in type 2 diabetes. PLoS One 10: 1–10.
    [15] Losin IE, Shakhnovich RM, Zykov KA, et al. (2014) Cardiovascular diseases and mannose-binding lectin. Kardiologiia 54: 64–70.
    [16] Kelsall A, Fitzgerald AJ, Howard CV, et al. (2002) Dietary lectins can stimulate pancreatic growth in the rat. Int J Exp Pathol 83: 203–208. doi: 10.1046/j.1365-2613.2002.00230.x
    [17] Hoyem PH, Bruun JM, Pedersen SB, et al. (2012) The effect of weight loss on serum mannose-binding lectin levels. Clin Dev Immunol 2012: 1–5.
    [18] Akkouh O, Ng TB, Singh SS, et al. (2015) Lectins with anti-HIV activity: A review. Molecules 20: 648–668. doi: 10.3390/molecules20010648
    [19] Checkley MA, Luttge BG, Freed EO (2011) HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol 410: 582–608. doi: 10.1016/j.jmb.2011.04.042
    [20] Balzarini J, Van LK, Hatse S, et al. (2004) Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. J Virol 78: 10617–10627. doi: 10.1128/JVI.78.19.10617-10627.2004
    [21] Huskens D, Van LK, Vermeire K, et al. (2007) Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. Virology 360: 294–304. doi: 10.1016/j.virol.2006.10.027
    [22] Blumenthal R, Durell S, Viard M (2012) HIV entry and envelope glycoprotein-mediated fusion. J Biol Chem 287: 40841–40849. doi: 10.1074/jbc.R112.406272
    [23] Wilen CB, Tilton JC, Doms RW (2012) HIV: Cell binding and entry. Cold Spring Harb Perspect Med 2: 1–13
    [24] Ratner L, Haseltine W, Patarca R, et al. (1985) Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313: 277–284. doi: 10.1038/313277a0
    [25] Allan JS, Coligan JE, Barin F, et al. (1985) Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228: 1091–1094. doi: 10.1126/science.2986290
    [26] Montagnier L, Clavel F, Krust B, et al. (1985) Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy-associated virus. Virology 144: 283–289. doi: 10.1016/0042-6822(85)90326-5
    [27] Wainhobson S, Sonigo P, Danos O, Cole S, et al. (1985) Nucleotide sequence of the AIDS virus, LAV. Cell 40: 9–17. doi: 10.1016/0092-8674(85)90303-4
    [28] Mizuochi T, Spellman MW, Larkin M, et al. (1988) Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells. Biochem J 254: 599–603. doi: 10.1042/bj2540599
    [29] Mizuochi T, Spellman MW, Larkin M, et al. (1988) Structural characterization by chromatographic profiling of the oligosaccharides of human immunodeficiency virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese hamster ovary cells. Biomed Chromatogr 2: 260–270.
    [30] Mizuochi T, Matthews TJ, Kato M, et al. (1990) Diversity of oligosaccharide structures on the envelope glycoprotein gp120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues. J Biol Chem 265: 8519–8524.
    [31] Geyer H, Holschbach C, Hunsmann G, et al. (1988) Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. J Biol Chem 263: 11760–11767.
    [32] Go EP, Hewawasam G, Liao HX, et al. (2011) Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J Virol 85: 8270–8284. doi: 10.1128/JVI.05053-11
    [33] Bonomelli C, Doores KJ, Dunlop DC, et al. (2011) The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 6: 1–7.
    [34] Go EP, Herschhorn A, Gu C, et al. (2015) Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140. J Virol 89: 8245–8257. doi: 10.1128/JVI.00628-15
    [35] Raska M, Takahashi K, Czernekova L, et al. (2010) Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem 285: 20860–20869. doi: 10.1074/jbc.M109.085472
    [36] Zhu X, Borchers C, Bienstock RJ, et al. (2000) Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39: 11194–11204. doi: 10.1021/bi000432m
    [37] Doores KJ, Bonomelli C, Harvey DJ, et al. (2010) Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A 107: 13800–13805. doi: 10.1073/pnas.1006498107
    [38] Behrens AJ, Harvey DJ, Milne E, et al. (2017) Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer. J Virol 91: 1–16.
    [39] Sok D, Doores KJ, Briney B, et al. (2014) Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med 6: 1–15.
    [40] Pritchard LK, Spencer DI, Royle L, et al. (2015) Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nat Commun 6: 1–11.
    [41] Coss KP, Vasiljevic S, Pritchard LK, et al. (2016) HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual. J Virol 90: 11132–11144. doi: 10.1128/JVI.01542-16
    [42] Raska M, Novak J (2010) Involvement of envelope-glycoprotein glycans in HIV-1 biology and infection. Arch Immunol Ther Exp 58: 191–208. doi: 10.1007/s00005-010-0072-3
    [43] Wang SK, Liang PH, Astronomo RD, et al. (2008) Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci U S A 105: 3690–3695. doi: 10.1073/pnas.0712326105
    [44] Balzarini J (2005) Targeting the glycans of gp120: A novel approach aimed at the Achilles heel of HIV. Lancet Infect Dis 5: 726–731. doi: 10.1016/S1473-3099(05)70271-1
    [45] Koch M, Pancera M, Kwong PD, et al. (2003) Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313: 387–400. doi: 10.1016/S0042-6822(03)00294-0
    [46] Rathore U, Saha P, Kesavardhana S, et al. (2017) Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity. J Biol Chem 24: 10197–10219.
    [47] Sanders RW, Anken EV, Nabatov AA, et al. (2008) The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology 5: 1–15. doi: 10.1186/1742-4690-5-1
    [48] Montefiori DC, Jr RW, Mitchell WM (1988) Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 85: 9248–9252. doi: 10.1073/pnas.85.23.9248
    [49] Francois KO, Balzarini J (2011) The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry. J Biol Chem 286: 42900–42910. doi: 10.1074/jbc.M111.274456
    [50] Mathys L, Francois KO, Quandte M, et al. (2014) Deletion of the highly conserved N-glycan at Asn260 of HIV-1 gp120 affects folding and lysosomal degradation of gp120, and results in loss of viral infectivity. PLoS One 9: 1–11.
    [51] Huang X, Jin W, Hu K, et al. (2012) Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. Virology 423: 97–106. doi: 10.1016/j.virol.2011.11.023
    [52] Binley JM, Ban YE, Crooks ET, et al. (2010) Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol 84: 5637–5655. doi: 10.1128/JVI.00105-10
    [53] Li Y, Luo L, Rasool N, et al. (1993) Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding. J Virol 67: 584–588.
    [54] Li H, Jr CP, Tuen M, Visciano ML, et al. (2008) Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes. J Immunol 180: 4011–4021. doi: 10.4049/jimmunol.180.6.4011
    [55] Behrens AJ, Vasiljevic S, Pritchard LK, et al. (2016) Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. Cell Rep 14: 2695–2706. doi: 10.1016/j.celrep.2016.02.058
    [56] Pritchard LK, Vasiljevic S, Ozorowski G, et al. (2015) Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. Cell Rep 11: 1604–1613. doi: 10.1016/j.celrep.2015.05.017
    [57] Steckbeck JD, Craigo JK, Barnes CO, et al. (2011) Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: Implications for functions in viral replication. J Biol Chem 286: 27156–27166. doi: 10.1074/jbc.M111.258855
    [58] Dimonte S, Mercurio F, Svicher V, et al. (2011) Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v(3) signatures in the regulation of co-receptor usage. Retrovirology 8: 1–11. doi: 10.1186/1742-4690-8-1
    [59] Perrin C, Fenouillet E, Jones IM (1998) Role of gp41 glycosylation sites in the biological activity of human immunodeficiency virus type 1 envelope glycoprotein. Virology 242: 338–345. doi: 10.1006/viro.1997.9016
    [60] Johnson WE, Sauvron JM, Desrosiers RC (2001) Conserved, N-linked carbohydrates of human immunodeficiency virus type 1 gp41 are largely dispensable for viral replication. J Virol 75: 11426–11436. doi: 10.1128/JVI.75.23.11426-11436.2001
    [61] Fenouillet E (1993) La N-glycosylation du VIH: Du modèle expérimental à l'application thérapeutique. J Libbery Eurotext Montrouge 9: 901–906.
    [62] Fenouillet E, Jones IM (1995) The glycosylation of human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) is important for the efficient intracellular transport of the envelope precursor gp160. J Gen Virol 76: 1509–1514. doi: 10.1099/0022-1317-76-6-1509
    [63] Lee WR, Yu XF, Syu WJ, et al. (1992) Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41. J Virol 66: 1799–1803.
    [64] Ma BJ, Alam SM, Go EP, et al. (2011) Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog 7: 1–16.
    [65] Wang LX, Song H, Liu S, et al. (2005) Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: Effects of glycosylation on the anti-HIV activity and alpha-helix bundle-forming ability of peptide C34. Chembiochem 6: 1068–1074. doi: 10.1002/cbic.200400440
    [66] Balzarini J, Van LK, Hatse S, et al. (2005) Carbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV GP120: A new therapeutic concept to hit the achilles heel of HIV. J Biol Chem 280: 41005–41014. doi: 10.1074/jbc.M508801200
    [67] Van AE, Sanders RW, Liscaljet IM, et al. (2008) Only five of 10 strictly conserved disulfide bonds are essential for folding and eight for function of the HIV-1 envelope glycoprotein. Mol Biol Cell 19: 4298–4309. doi: 10.1091/mbc.E07-12-1282
    [68] Mathys L, Balzarini J (2014) The role of N-glycans of HIV-1 gp41 in virus infectivity and susceptibility to the suppressive effects of carbohydrate-binding agents. Retrovirology 11: 1–18. doi: 10.1186/1742-4690-11-1
    [69] Fenouillet E, Jones I, Powell B, et al. (1993) Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain. J Virol 67: 150–160.
    [70] Yuste E, Bixby J, Lifson J, et al. (2008) Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies. J Virol 82: 12472–12486. doi: 10.1128/JVI.01382-08
    [71] Tanaka H, Chiba H, Inokoshi J, et al. (2009) Mechanism by which the lectin actinohivin blocks HIV infection of target cells. Proc Natl Acad Sci U S A 106: 15633–15638. doi: 10.1073/pnas.0907572106
    [72] Hoorelbeke B, Huskens D, Ferir G, et al. (2010) Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope. Antimicrob Agents Chemother 54: 3287–32301. doi: 10.1128/AAC.00254-10
    [73] Zhang F, Hoque MM, Jiang J, et al. (2014) The characteristic structure of anti-HIV actinohivin in complex with three HMTG D1 chains of HIV-gp120. Chembiochem 15: 2766–2773. doi: 10.1002/cbic.201402352
    [74] Bewley CA, Gustafson KR, Boyd MR, et al. (1998) Solution structure of cyanovirin-N, a potent HIV-inactivating protein. Nat Struct Biol 5: 571–578. doi: 10.1038/828
    [75] Barrientos LG, Louis JM, Ratner DM, et al. (2003) Solution structure of a circular-permuted variant of the potent HIV-inactivating protein cyanovirin-N: Structural basis for protein stability and oligosaccharide interaction. J Mol Biol 325: 211–223. doi: 10.1016/S0022-2836(02)01205-6
    [76] Esser MT, Mori T, Mondor I, et al. (1999) Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J Virol 73: 4360–4371.
    [77] Alexandre KB, Gray ES, Mufhandu H, et al. (2012) The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells. Virology 423: 175–186. doi: 10.1016/j.virol.2011.12.001
    [78] Buffa V, Stieh D, Mamhood N, et al. (2009) Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J Gen Virol 90: 234–243. doi: 10.1099/vir.0.004358-0
    [79] Boyd MR, Gustafson KR, Mcmahon JB, et al. (1997) Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development. Antimicrob Agents Chemother 41: 1521–1530.
    [80] Hu Q, Mahmood N, Shattock RJ (2007) High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology 368: 145–154. doi: 10.1016/j.virol.2007.06.029
    [81] Keeffe JR, Gnanapragasam PN, Gillespie SK, et al. (2011) Designed oligomers of cyanovirin-N show enhanced HIV neutralization. Proc Natl Acad Sci U S A 108: 14079–14084. doi: 10.1073/pnas.1108777108
    [82] Dey B, Lerner DL, Lusso P, et al. (2000) Multiple antiviral activities of cyanovirin-N: Blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol 74: 4562–4569. doi: 10.1128/JVI.74.10.4562-4569.2000
    [83] Férir G, Huskens D, Noppen S, et al. (2014) Broad anti-HIV activity of the Oscillatoria agardhii agglutinin homologue lectin family. J Antimicrob Chemother 69: 2746–2758. doi: 10.1093/jac/dku220
    [84] Koharudin LM, Gronenborn AM (2011) Structural basis of the anti-HIV activity of the cyanobacterial Oscillatoria Agardhii agglutinin. Structure 19: 1170–1181. doi: 10.1016/j.str.2011.05.010
    [85] Koharudin LM, Furey W, Gronenborn AM (2011) Novel fold and carbohydrate specificity of the potent anti-HIV cyanobacterial lectin from Oscillatoria agardhii. J Biol Chem 286: 1588–1597. doi: 10.1074/jbc.M110.173278
    [86] Carneiro MG, Koharudin LM, Ban D, et al. (2015) Sampling of Glycan-Bound Conformers by the Anti-HIV Lectin Oscillatoria agardhii agglutinin in the Absence of Sugar. Angew Chem 54: 6462–6465. doi: 10.1002/anie.201500213
    [87] Bokesch HR, O'Keefe BR, Mckee TC, et al. (2003) A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Biochemistry 42: 2578–2584. doi: 10.1021/bi0205698
    [88] Adams EW, Ratner DM, Bokesch HR, et al. (2004) Oligosaccharide and glycoprotein microarrays as tools in HIV glycobiology; glycan-dependent gp120/protein interactions. Chem Biol 11: 875–881. doi: 10.1016/j.chembiol.2004.04.010
    [89] Mcfeeters RL, Xiong C, O'Keefe BR, et al. (2007) The novel fold of scytovirin reveals a new twist for antiviral entry inhibitors. J Mol Biol 369: 451–461. doi: 10.1016/j.jmb.2007.03.030
    [90] Alexandre KB, Gray ES, Lambson BE, et al. (2010) Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology 402: 187–196. doi: 10.1016/j.virol.2010.03.021
    [91] Williams DC, Lee JY, Cai M, et al. (2005) Crystal structures of the HIV-1 inhibitory cyanobacterial protein MVL free and bound to Man3GlcNAc2: Structural basis for specificity and high-affinity binding to the core pentasaccharide from n-linked oligomannoside. J Biol Chem 280: 29269–29276. doi: 10.1074/jbc.M504642200
    [92] Ziółkowska NE, Wlodawer A (2006) Structural studies of algal lectins with anti-HIV activity. Acta Biochim Pol 53: 617–626.
    [93] Shahzadulhussan S, Gustchina E, Ghirlando R, et al. (2011) Solution structure of the monovalent lectin microvirin in complex with Man(alpha)(1–2)Man provides a basis for anti-HIV activity with low toxicity. J Biol Chem 286: 20788–20796. doi: 10.1074/jbc.M111.232678
    [94] Huskens D, Ferir G, Vermeire K, et al. (2010) Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile. J Biol Chem 285: 24845–24854. doi: 10.1074/jbc.M110.128546
    [95] López S, Armandugon M, Bastida J, et al. (2003) Anti-human immunodeficiency virus type 1 (HIV-1) activity of lectins from Narcissus species. Planta Med 69: 109–112. doi: 10.1055/s-2003-37715
    [96] Müller WEG, Forrest JMS, Chang SH, et al. (1991) Narcissus and Gerardia lectins: Tools for the development of a vaccine against AIDS and a new ELISA to quantify HIV-gp 120. Lectins Cancer 1991: 27–40.
    [97] Charan RD, Munro MH, O'Keefe BR, et al. (2000) Isolation and characterization of Myrianthus holstii lectin, a potent HIV-1 inhibitory protein from the plant Myrianthus holstii(1). J Nat Prod 63: 1170–1174. doi: 10.1021/np000039h
    [98] Coulibaly FS, Youan BB (2014) Concanavalin A-polysaccharides binding affinity analysis using a quartz crystal microbalance. Biosens Bioelectron 59: 404–411. doi: 10.1016/j.bios.2014.03.040
    [99] Bhattacharyya L, Brewer CF (1989) Interactions of concanavalin A with asparagine-linked glycopeptides. Structure/activity relationships of the binding and precipitation of oligomannose and bisected hybrid-type glycopeptides with concanavalin A. Eur J Biochem 178: 721–726.
    [100] Witvrouw M, Fikkert V, Hantson A, et al. (2005) Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. J Virol 79: 7777–7784. doi: 10.1128/JVI.79.12.7777-7784.2005
    [101] Hansen JE, Nielsen CM, Nielsen C, et al. (1989) Correlation between carbohydrate structures on the envelope glycoprotein gp120 of HIV-1 and HIV-2 and syncytium inhibition with lectins. Aids 3: 635–641. doi: 10.1097/00002030-198910000-00003
    [102] Matsui T, Kobayashi S, Yoshida O, et al. (1990) Effects of succinylated concanavalin A on infectivity and syncytial formation of human immunodeficiency virus. Med Microbiol Immunol 179: 225–235.
    [103] Pashov A, Macleod S, Saha R, et al. (2005) Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12. Glycobiology 15: 994–1001. doi: 10.1093/glycob/cwi083
    [104] Swanson MD, Boudreaux DM, Salmon L, et al. (2015) Engineering a therapeutic lectin by uncoupling mitogenicity from antiviral activity. Cell 163: 746–758. doi: 10.1016/j.cell.2015.09.056
    [105] Alexandre KB, Gray ES, Pantophlet R, et al. (2011) Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. J Virol 85: 9039–9050. doi: 10.1128/JVI.02675-10
    [106] Mori T, O'Keefe BR, Bringans S, et al. (2005) Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem 280: 9345–9353. doi: 10.1074/jbc.M411122200
    [107] Emau P, Tian B, O'Keefe BR, et al. (2007) Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J Med Primatol 36: 244–253. doi: 10.1111/j.1600-0684.2007.00242.x
    [108] Moulaei T, Alexandre KB, Shenoy SR, et al. (2015) Griffithsin tandemers: Flexible and potent lectin inhibitors of the human immunodeficiency virus. Retrovirology 12: 1–14. doi: 10.1186/s12977-014-0129-1
    [109] Zhou X, Liu J, Yang B, et al. (2013) Marine natural products with anti-HIV activities in the last decade. Curr Med Chem 20: 953–973.
    [110] Wang JH, Kong J, Li W, et al. (2006) A beta-galactose-specific lectin isolated from the marine worm Chaetopterus variopedatus possesses anti-HIV-1 activity. Comp Biochem Physiol C Toxicol Pharmacol 142: 111–117. doi: 10.1016/j.cbpc.2005.10.019
    [111] Bulgheresi S, Schabussova I, Chen T, et al. (2006) A new C-type lectin similar to the human immunoreceptor DC-SIGN mediates symbiont acquisition by a marine nematode. Appl Environ Microbiol 72: 2950–2956. doi: 10.1128/AEM.72.4.2950-2956.2006
    [112] Nabatov AA, Jong MAWPD, Witte LD, et al. (2008) C-type lectin Mermaid inhibits dendritic cell mediated HIV-1 transmission to CD4+ T cells. Virology 378: 323–328. doi: 10.1016/j.virol.2008.05.025
    [113] Molchanova V, Chikalovets I, Chernikov O, et al. (2007) A new lectin from the sea worm Serpula vermicularis: Isolation, characterization and anti-HIV activity. Comp Biochem Physiol C Toxicol Pharmacol 145: 184–193. doi: 10.1016/j.cbpc.2006.11.012
    [114] Vo TS, Kim SK (2010) Potential anti-HIV agents from marine resources: An overview. Mar Drugs 8: 2871–2892. doi: 10.3390/md8122871
    [115] Mahalingam A, Geonnotti AR, Balzarini J, et al. (2011) Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry. Mol Pharmaceutics 8: 2465–2475. doi: 10.1021/mp2002957
    [116] Berube M, Dowlut M, Hall DG (2008) Benzoboroxoles as efficient glycopyranoside-binding agents in physiological conditions: Structure and selectivity of complex formation. J Org Chem 73: 6471–6479. doi: 10.1021/jo800788s
    [117] Trippier PC, Mcguigan C, Balzarini J (2010) Phenylboronic-acid-based carbohydrate binders as antiviral therapeutics: Monophenylboronic acids. Antivir Chem Chemother 20: 249–257.
    [118] Trippier PC, Balzarini J, Mcguigan C (2011) Phenylboronic-acid-based carbohydrate binders as antiviral therapeutics: Bisphenylboronic acids. Antivir Chem Chemother 21: 129–142.
    [119] Khan JM, Qadeer A, Ahmad E, et al. (2013) Monomeric banana lectin at acidic pH overrules conformational stability of its native dimeric form. PLoS One 8: 1–12.
    [120] Suzuki K, Ohbayashi N, Jiang J, et al. (2012) Crystallographic study of the interaction of the anti-HIV lectin actinohivin with the alpha(1-2)mannobiose moiety of gp120 HMTG. Acta Crystallogr Sect F Struct Biol Cryst Commun 68: 1060–1063. doi: 10.1107/S1744309112031077
    [121] Tevibénissan C, Bélec L, Lévy M, et al. (1997) In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin Diagn Lab Immunol 4: 367–374.
    [122] Ballerstadt R, Evans C, Mcnichols R, et al. (2006) Concanavalin A for in vivo glucose sensing: A biotoxicity review. Biosens Bioelectron 22: 275–284. doi: 10.1016/j.bios.2006.01.008
    [123] Krauss S, Buttgereit F, Brand MD (1999) Effects of the mitogen concanavalin A on pathways of thymocyte energy metabolism. Biochim Biophys Acta 1412: 129–138. doi: 10.1016/S0005-2728(99)00058-4
    [124] Balzarini J, Laethem KV, Peumans WJ, et al. (2006) Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol 80: 8411–8421. doi: 10.1128/JVI.00369-06
    [125] Gavrovicjankulovic M, Poulsen K, Brckalo T, et al. (2008) A novel recombinantly produced banana lectin isoform is a valuable tool for glycoproteomics and a potent modulator of the proliferation response in CD3+, CD4+, and CD8+ populations of human PBMCs. Int J Biochem Cell Biol 40: 929–941. doi: 10.1016/j.biocel.2007.10.033
    [126] Mahalingam A, Geonnotti AR, Balzarini J, et al. (2011) Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry. Mol Pharm 8: 2465–2475. doi: 10.1021/mp2002957
    [127] Lam SK, Ng TB (2011) Lectins: Production and practical applications. Appl Microbiol Biotechnol 89: 45–55. doi: 10.1007/s00253-010-2892-9
    [128] Scanlan CN, Offer J, Zitzmann N, et al. (2007) Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 446: 1038–1045. doi: 10.1038/nature05818
    [129] Gupta A, Gupta RK, Gupta GS (2009) Targeting cells for drug and gene delivery: Emerging applications of mannans and mannan binding lectins. J Sci Ind Res 68: 465–483.
    [130] Ghazarian H, Idoni B, Oppenheimer SB (2011) A glycobiology review: Carbohydrates, lectins and implications in cancer therapeutics. Acta Histochem 113: 236–247. doi: 10.1016/j.acthis.2010.02.004
    [131] Toda S, Ishii N, Okada E, et al. (1997) HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody. Immunology 92: 111–117. doi: 10.1046/j.1365-2567.1997.00307.x
    [132] Zelensky AN, Gready JE (2005) The C-type lectin-like domain superfamily. FEBS J 272: 6179–6217. doi: 10.1111/j.1742-4658.2005.05031.x
    [133] Cui Z, Hsu CH, Mumper RJ (2003) Physical characterization and macrophage cell uptake of mannan-coated nanoparticles. Drug Dev Ind Pharm 29: 689–700. doi: 10.1081/DDC-120021318
    [134] Espuelas S, Thumann C, Heurtault B, et al. (2008) Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes. Bioconjugate Chem 19: 2385–2393. doi: 10.1021/bc8002524
    [135] Zhang Q, Su L, Collins J, et al. (2014) Dendritic cell lectin-targeting sentinel-like unimolecular glycoconjugates to release an anti-HIV drug. J Am Chem Soc 136: 4325–4332. doi: 10.1021/ja4131565
    [136] Hong PWP, Flummerfelt KB, Parseval AD, et al. (2002) Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: Implications for structural analyses of gp120-DC-SIGN binding. J Virol 76: 12855–12865. doi: 10.1128/JVI.76.24.12855-12865.2002
    [137] Cruz LJ, Tacken PJ, Fokkink R, et al. (2010) Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Controlled Release 144: 118–126. doi: 10.1016/j.jconrel.2010.02.013
    [138] Ingale J, Stano A, Guenaga J, et al. (2016) High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. Cell Rep 15: 1986–1999. doi: 10.1016/j.celrep.2016.04.078
    [139] He L, Val ND, Morris CD, et al. (2016) Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. Nat Commun 7: 1–15.
    [140] Akashi M, Niikawa T, Serizawa T, et al. (1998) Capture of HIV-1 gp120 and virions by lectin-immobilized polystyrene nanospheres. Bioconjugate Chem 9: 50–53. doi: 10.1021/bc970045y
    [141] Hayakawa T, Kawamura M, Okamoto M, et al. (1998) Concanavalin A-immobilized polystyrene nanospheres capture HIV-1 virions and gp120: Potential approach towards prevention of viral transmission. J Med Virol 56: 327–331. doi: 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
    [142] Coulibaly FS, Ezoulin MJM, Purohit SS, et al. (2017) Layer-by-layer engineered microbicide drug delivery system targeting HIV-1 gp120: Physicochemical and biological properties. Mol Pharm 14: 3512–3527.
    [143] Takahashi K, Moyo P, Chigweshe L, et al. (2013) Efficacy of recombinant chimeric lectins, consisting of mannose binding lectin and L-ficolin, against influenza A viral infection in mouse model study. Virus Res 178: 495–501. doi: 10.1016/j.virusres.2013.10.001
    [144] Sato Y, Morimoto K, Kubo T, et al. (2015) Entry Inhibition of Influenza Viruses with High Mannose Binding Lectin ESA-2 from the Red Alga Eucheuma serra through the Recognition of Viral Hemagglutinin. Mar Drugs 13: 3454–3465. doi: 10.3390/md13063454
    [145] Kachko A, Loesgen S, Shahzad-Ul-Hussan S, et al. (2013) Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: Mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA. Mol Pharmaceutics 10: 4590–4602. doi: 10.1021/mp400399b
    [146] Gadjeva M, Paludan SR, Thiel S, et al. (2004) Mannan-binding lectin modulates the response to HSV-2 infection. Clin Exp Immunol 138: 304–311. doi: 10.1111/j.1365-2249.2004.02616.x
    [147] Eisen S, Dzwonek A, Klein NJ (2008) Mannose-binding lectin in HIV infection. Future Virol 3: 225–233. doi: 10.2217/17460794.3.3.225
    [148] Ji X, Olinger GG, Aris S, et al. (2005) Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J Gen Virol 86: 2535–2542. doi: 10.1099/vir.0.81199-0
    [149] Keyaerts E, Vijgen L, Pannecouque C, et al. (2007) Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Res 75: 179–187. doi: 10.1016/j.antiviral.2007.03.003
    [150] Hamel R, Dejarnac O, Wichit S, et al. (2015) Biology of Zika Virus Infection in Human Skin Cells. J Virol 89: 8880–8896. doi: 10.1128/JVI.00354-15
    [151] Clement F, Venkatesh YP (2010) Dietary garlic (Allium sativum) lectins, ASA I and ASA II, are highly stable and immunogenic. Int Immunopharmacol 10: 1161–1169. doi: 10.1016/j.intimp.2010.06.022
    [152] Lusvarghi S, Bewley CA (2016) Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential. Viruses 8: 1–18.
  • This article has been cited by:

    1. Akhil Kumar Srivastav, Pankaj Kumar Tiwari, Mini Ghosh, Modeling the impact of early case detection on dengue transmission: deterministic vs. stochastic, 2020, 0736-2994, 1, 10.1080/07362994.2020.1804403
    2. Mayra R. Tocto-Erazo, Daniel Olmos-Liceaga, José A. Montoya-Laos, Effect of daily human movement on some characteristics of dengue dynamics, 2021, 332, 00255564, 108531, 10.1016/j.mbs.2020.108531
    3. Benjamin Ambrosio, M. A. Aziz-Alaoui, On a Coupled Time-Dependent SIR Models Fitting with New York and New-Jersey States COVID-19 Data, 2020, 9, 2079-7737, 135, 10.3390/biology9060135
    4. Léa Douchet, Marion Haramboure, Thierry Baldet, Gregory L’Ambert, David Damiens, Louis Clément Gouagna, Jeremy Bouyer, Pierrick Labbé, Annelise Tran, Comparing sterile male releases and other methods for integrated control of the tiger mosquito in temperate and tropical climates, 2021, 11, 2045-2322, 10.1038/s41598-021-86798-8
    5. Harrison Watts, Arti Mishra, Dang H. Nguyen, Tran D. Tuong, Dynamics of a vector-host model under switching environments, 2021, 0, 1553-524X, 0, 10.3934/dcdsb.2021029
    6. José A. Montoya, Gudelia Figueroa-Preciado, Mayra Rosalia Tocto-Erazo , FLAT LIKELIHOODS: SIR-POISSON MODEL CASE, 2022, 11, 2357-5549, 74, 10.15446/rev.fac.cienc.v11n2.100986
    7. Lorena Pujante-Otalora, Bernardo Canovas-Segura, Manuel Campos, Jose M. Juarez, The use of networks in spatial and temporal computational models for outbreak spread in epidemiology: A systematic review, 2023, 15320464, 104422, 10.1016/j.jbi.2023.104422
    8. Masoud Mardani, Locally Transmitted Dengue Fever in Iran: A Growing Concern, 2024, 19, 2345-2641, 10.5812/archcid-153959
    9. 可 张, Two Release Strategies of Sterile Mosquitoes under Weak Allee Effect, 2025, 14, 2324-7991, 303, 10.12677/aam.2025.141031
    10. Boqi Dong, Sisi Feng, Xianmin Feng, Advances in the Epidemiology, Pathogenesis, Diagnostic Methods, and Vaccine Development of Dengue Fever: A Comprehensive Review, 2025, 0882-8245, 10.1089/vim.2024.0087
  • Reader Comments
  • © 2018 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(7605) PDF downloads(2120) Cited by(6)

Figures and Tables

Figures(2)  /  Tables(2)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog